Positive Results from Interim Analysis of ' GEN-001 ' Plus avelumab (Bavencio) Phase II Trial

SEOUL, South Korea, May 19, 2023. Genome& Company  a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials